Introduction
============

Ginsenoside Rg3, which has the chemical name of 12β, 20-dihydroxydammar-24-en-3β-yl2-O-β-D-glucopyranosyl-β- D-glucopyranoside, and ginsenoside Rg3 exist in two forms, the R type and S type, according to its asymmetric carbon atom (choral carbon atom) C20. Ginsenoside Rg3 has diverse pharmacological effects *in vitro* and *in vivo* via the activation or repression of the expression of different genes. Previous studies have reported that ginsenoside Rg3 inhibits cancer cell proliferation and induces apoptosis by decreasing the expression of histone deacetylase 3 ([@b1-mmr-15-04-2029]), epidermal growth factor receptor ([@b2-mmr-15-04-2029]), fucosyltransferase IV ([@b3-mmr-15-04-2029]) and vascular endothelial growth factor (VEGF) ([@b4-mmr-15-04-2029]), and upregulates the protein expression of pro-apoptotic P53 ([@b1-mmr-15-04-2029]), caspase-3, caspase-8 and caspase-9 ([@b5-mmr-15-04-2029]). Ginsenoside Rg3 has been shown to enhance the radiosensitivity of human esophageal carcinoma cells by downregulating the expression of VEGF and hypoxia inducible factor-1α ([@b6-mmr-15-04-2029]), and ginsenoside Rg3 may have a neuroprotective function in the rat hippocampus via the inhibition of hippocampus-mediated N-methyl-D-aspartate receptor activation ([@b7-mmr-15-04-2029]). Additional biological activities associated with gene regulation have also been demonstrated for this molecule ([@b2-mmr-15-04-2029],[@b8-mmr-15-04-2029]).

5-methyl-cytosine (m5Cyt) is the most investigated epigenetic modification, and alterations in genomic DNA methylation patterns have been confirmed to be associated with the development of pathological processes and diseases, including cancer ([@b9-mmr-15-04-2029],[@b10-mmr-15-04-2029]). It has also been reported that DNA methylation patterns can be altered by medication, nutrients and chemicals ([@b11-mmr-15-04-2029]--[@b13-mmr-15-04-2029]). DNA methyltransferases (DNMTs) are enzymes responsible for establishing the original methylation patterns of *de novo* methylases, DNMT3a and DNMT3b, and for maintaining these throughout subsequent cellular divisions (maintenance methylase DNMT1). However, until now, there have been no reports on whether ginsenoside Rg3 affects DNA methylation or the expression of methyltransferases.

Global hypomethylation and promoter hypermethylation have been found in hepatocarcinogenesis ([@b14-mmr-15-04-2029]--[@b16-mmr-15-04-2029]); therefore, the present study investigated the effects of ginsenoside Rg3 on methylation in the HepG2 human hepatocarcinoma cell line. The results showed that ginsenoside Rg3 inhibited HepG2 cell proliferation in a dose-dependent manner, induced a reduction in global DNA methylation, altered methylated cystosines in the promoter regions of specific genes, upregulated the expression of DNMT1, and downregulated the expression of DNMT3a and DNMT 3b. In addition, the different ginsenoside Rg3 epimers exhibited different biological activities.

Materials and methods
=====================

### Reagents

High performance liquid chromatography (HPLC)-grade standards for 20(S)-ginsenoside Rg3 and 20(R)-ginsenoside Rg3 were purchased from Shanghai Yuanye Biotechnology Co., Ltd. (Shanghai, China) and dissolved at a concentration of 50 mg/ml in dimethyl sulfoxide as a stock solution (stored at −20°C). This solution was then further diluted in cell culture medium to prepare the working concentrations (0, 7.81, 15.63, 31.25, 62.5, 125, 250 and 500 µg/ml). 5-methyl-2′-deoxycytidine (5-MedC) was purchased from United States Biological (Salem, MA, USA), and 2′-deoxyguanosine (dG), thymidine (T), 2′-deoxycytidine (dC) and 2′-deoxyadenosine (dA) were obtained from Sigma-Aldrich; Merck Millipore (Darmstadt, Germany). Sodium acetate, ammonium formate and acetonitrile were supplied by Beijing Chemical Works (Beijing, China). MNase, nuclease P1 and alkaline phosphatase were purchased from Takara Bio, Inc. (Otsu, Japan).

### Analysis of cell viability

Cell proliferation was measured using a Cell Counting Kit-8 (CCK8; Beyotime Institute of Biotechnology, Inc., Jiangsu, China). Briefly, cells of the human hepatocarcinoma cell line HepG2 were cultured in RPMI-1640 supplemented with 10% fetal bovine serum (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 1% antibiotics-antimycotics in a humidified 5% CO~2~ atmosphere at 37°C. Exponentially growing cells were seeded in a 96-well plate at a density of 1.0×10^4^ cells/well. The following day, the cells were treated in triplicate with the various concentrations of 20(S)-ginsenoside Rg3 or 20(R)-ginsenoside Rg3 for 24 h at 37°C. Following incubation for 24 h, cell viability was assessed using the CCK8 assay, according to the manufacturer\'s protocol. Finally, the absorbance value was recorded at an optical density of 450 nm (OD~450~) using an enzyme-linked immunosorbent assay plate reader (Emax Plus; Molecular Devices, LLC, Sunnyvale, CA, USA). At least three independent experiments were performed, and the experiments involved three groups: Untreated HepG2 cells (not treated with ginsenoside Rg3), HepG2 cells treated with various concentrations of 20(S)-ginsenoside Rg3 or 20(R)-ginsenoside Rg3 as the experimental group, and a blank group of cell culture only. The inhibition rate was calculated using the following formula: \[(untreated group OD~450~-experimental group OD~450~)/(untreated group OD~450~-blank group OD~450~)\]x100%.

### Measurement of global DNA methylation using HPLC

HPLC analysis was performed on a liquid chromatograph coupled with a Waters 2489 UV/visible detector (Waters Corporation, Milford, MA, USA). Separation was achieved on a Symmetry^®^ C18 (5 µm; 4.6×250) column (Waters Corporation). The mobile phase consisted of solvent A (50 mM ammonium formate; pH 5.4) and solvent B (HPLC-grade acetonitrile). The following gradient program used was: Solvent B 2% at 0 min, solvent B 3% at 18 min, solvent B 27% at 25 min, solvent B 35% at 40 min and solvent B 2% at 45 min. The total duration of analysis was 50 min. The flow rate was set at 0.2 ml/min and the column oven temperature was maintained at 25°C. UV detection was performed at 277 nm.

The concentrations of MedC and dC were calculated from linear regression curves, and the percentage of methylation was then calculated using the following equation: 5-MedC (%)=\[5-MedC/(dC+MedC)\]x100.

### Preparation of standards

The 5-MedC, dC, dA, dT and dG stock standard solutions were prepared by diluting purchased powder in appropriate volumes of HPLC grade water. All stock solutions were then mixed at an appropriate ratio to ensure all components were present at the same concentrations: 0.009765, 0.039625, 0.156250, 0.625000, 2.5 and 10 mM for 5-MedCand dC. All standard solutions were stored at −20°C and used within 1 week.

### DNA extraction and hydrolysis

Exponentially growing HepG2 cells were seeded at a density 5.0×10^5^ into 75 cm^2^ culture flasks and, following a 24 h period, the cells were either left untreated or were treated with 20(S)-ginsenoside Rg3 or 20(R)-ginsenoside Rg3, in accordance with the cell viability assessment. The cells were then collected, and DNA was purified using a Qiagen DNAeasy^®^ blood and tissue kit (Qiagen GmbH, Hilden, Germany).

Cryonase™ cold-active nuclease (Takara Bio, Inc.), micrococcal nuclease (Takara Bio, Inc.) and digestion buffer comprising 20 mM Tris-HCl, 5 mM NaCl and 2.5 mM CaCl~2~ (pH 8.0) were added to the purified DNA and incubated at 37°C overnight. Alkaline phosphatase (calf intestine; 1 unit/pmol; Takara Bio, Inc.) was added to the samples, and incubation was continued for an additional 4 h. The hydrolyzed DNA was then centrifuged at 18,000 × *g* for 20 min at 4°C and adjusted to an appropriate concentration (\~4 mM) in HPLC grade water for analysis using HPLC.

### MspI/HpaII polymerase chain reaction (PCR) assay

The *Msp*I/*Hpa*II PCR assay was performed as follows: Purified genomic DNA (2 µg) from the control and ginsenoside Rg3-treated samples were digested with 20 units of methylation-sensitive enzymes (*Msp*I or *Hpa*II) in a 20-µl reaction volume using the buffers supplied by the manufacturer (Takara Bio, Inc.). The reaction mixtures were incubated overnight at 37°C. The digested DNA samples were purified with phenol:chloroform:isoamyl alcohol (25:24:1) and chloroform extraction, followed by ethanol precipitation.

PCR was performed with the undigested and digested DNA from the control and ginsenoside Rg3-treated samples. A total of 40 primers were designed based on the sequences of the promoter regions of *Homo sapiens* B cell lymphoma 2 (Bcl2; NIH accession no. EU119400; [www.ncbi.nlm.nih.gov/nuccore/EU119400](www.ncbi.nlm.nih.gov/nuccore/EU119400)), *Homo sapiens* VEGF gene (NIH accession no. AF095785; [www.ncbi.nlm.nih.gov/nuccore/AF095785](www.ncbi.nlm.nih.gov/nuccore/AF095785)) and *Homo sapiens* tumor protein P53 (TP53; NIH accession no. NG_017013; [www.ncbi.nlm.nih.gov/nuccore/NG_017013](www.ncbi.nlm.nih.gov/nuccore/NG_017013)). Each set of primers spanned one or more CCGG sites of the target gene. The primer names, primer sequences and positions of the CCGG sequence for each gene are listed in [Table I](#tI-mmr-15-04-2029){ref-type="table"}. Each reaction mixture contained 1 µl DNA (\~10 ng), 10 µl Premix Taq™ DNA Polymerase Hot-Start (Takara Bio, Inc.), 1 µl DNA primer (0.5 µM) and 7 µl ddH~2~O. The reaction was denatured at 95°C for 5 min, followed by 40 cycles of 95°C for 15 sec, 55°C for 45 sec and 72°C for 1 min, with a final incubation step at 72°C for 5 min. Following agarose gel electrophoretic separation and staining with ethidium bromide, the amplified products were visualized under UV irradiation. Images were captured for further analysis.

### Reverse transcription-quantitative PCR (RT-qPCR) analysis

Total RNA was isolated from the cultured cells using the RNeasy^®^ Mini kit (Qiagen GmbH) according to the manufacturer\'s protocol. cDNA was synthesized using a ReverTrace qPCR RT kit (Toyobo Co., Ltd., Osaka, Japan) using an oligo-dT primer, and qPCR was then performed using SYBR^®^-Green Realtime PCR Master mix (Toyobo Co., Ltd.) with forward and reverse primers for each gene. The sequences of the qPCR primers are listed in [Table I](#tI-mmr-15-04-2029){ref-type="table"}. To avoid DNA contamination, at least one primer in each set spanned two exons. Each qPCR reaction mixture contained 1 µl cDNA, 10 µl SYBR^®^ Green Real-Time PCR Master Mix (Toyobo Co., Ltd.), 1 µl DNA primer (0.5 µM) and 7 µl ddH~2~O. The PCR was performed in a StepOnePlus™ (Applied Biosystems; Thermo Fisher Scientific, Inc.) with the following thermal cycling protocol: 95°C for 5 min, followed by 40 cycles at 95°C for 15 sec and then at 60°C for 40 sec. The relative expression level of each targeted gene was normalized to the expression of GAPDH calculated using the 2^−ΔΔCq^ quantification method ([@b17-mmr-15-04-2029]).

### Statistical analysis

All data were analyzed using descriptive one-way analysis of variance using the SPSS (version 16.0) software package (SPSS, Inc., Chicago, IL, USA). P\<0.05 was considered to indicate a statistically significant difference. All data are presented as the mean ± standard deviation.

Results
=======

### Antiproliferative effects of 20(S)-ginsenoside Rg3 are more marked, compared with those of 20(R)-ginsenoside Rg3

Ginsenoside Rg3 can exist as either the R type or S type according to its asymmetric carbon atom ([Fig. 1](#f1-mmr-15-04-2029){ref-type="fig"}). It has been reported that the antiproliferative effects of the different ginsenoside Rg3 epimers are cell line-dependent. Wu *et al* ([@b18-mmr-15-04-2029]) showed that the tumor inhibition rate achieved by 20(R)-ginsenoside Rg3 was significantly higher, compared with that by 20(S)-ginsenoside Rg3 in hepatoma (H22)-bearing mice. Kim *et al* ([@b19-mmr-15-04-2029]) found that the antiproliferative effect of 20(S)-ginsenoside Rg3 was higher, compared with that of 20(R)-ginsenoside Rg3 in A549 cells at the same concentration. Park *et al* ([@b20-mmr-15-04-2029]) reported that 20(S)-ginsenoside Rg3 reduced human gastric cancer cellular proliferation, whereas 20(R)-ginsenoside Rg3 had no effect. Cheong *et al* ([@b21-mmr-15-04-2029]) showed that 20(S)-ginsenoside Rg3 had higher cytotoxic potency, compared with the 20(R) epimer in HepG2 cells.

The present study confirmed the antiproliferative effects of 20(R)-ginsenoside Rg3 and 20(S)-ginsenoside Rg3 on the growth of HepG2 cells using a CCK8 assay, which offers higher sensitivity, compared with an MTT assay. The results ([Fig. 2A](#f2-mmr-15-04-2029){ref-type="fig"}) showed that treatment of cells with 20(S)-ginsenoside Rg3 over a concentration range of 15.63--500 µg/ml resulted in the inhibition of cellular proliferation, and the antiproliferative effect of 20(R)-ginsenoside Rg3 was observed over a concentration range of 31.25--500 µg/ml. Thus, the two epimers inhibited cellular proliferation in a concentration-dependent manner. As shown in [Fig. 2B](#f2-mmr-15-04-2029){ref-type="fig"}, the linear regression equation for 20(S)-ginsenoside Rg3 was Y=4.1296X-5.1012 (R^2^=0.9801) and the linear regression equation for 20(R)-ginsenoside Rg3 was Y=3.2054X-7.9504 (R^2^=0.9714). From these values, the LD50 of 20(S)-ginsenoside Rg3 was 178.03 µg/ml, whereas that of 20(R)-ginsenoside Rg3 was 326.84 µg/ml. Therefore, treatment with 20(S)-ginsenoside Rg3 resulted in more marked inhibition of cell growth, compared with treatment with 20(R)-ginsenoside Rg3. The doses selected for the treatment of cells in the subsequent experiments were 326.84 µg/ml 20(R)-ginsenoside Rg3 or 178.03 µg/ml 20(S)-ginsenoside Rg3.

### Ginsenoside Rg3 induces alterations in DNA methylation globally and in the promoter regions of specific genes

The HPLC method used in the present study was modified from that of Fragou *et al* ([@b22-mmr-15-04-2029]). In the present study, solvent B was changed from methanamide to acetonitrile, as acetonitrile was found to be more effective. From the HPLC chromatogram of standards, it was found that the C retention time was \~9 min and the 5-MedC retention time was \~16 min ([Fig. 3A](#f3-mmr-15-04-2029){ref-type="fig"}). The linear regression equation for C was Y=508781X+4356.14 (R^2^=0.99997; [Fig. 3B](#f3-mmr-15-04-2029){ref-type="fig"}), and the linear regression equation for MedC was Y=190820X+782.35 (R^2^=0.99999; [Fig. 3B](#f3-mmr-15-04-2029){ref-type="fig"}).

The alterations in DNA methylation in the untreated HepG2 cells and HepG2 cells treated with ginsenoside Rg3 are shown in [Fig. 4](#f4-mmr-15-04-2029){ref-type="fig"}. The data showed that the average DNA methylation was 3.56±0.125% in the untreated cells, 3.36±0.082% in the 20(R)-ginsenoside Rg3-treated cells (P=0.115, vs. untreated group) and 2.66±0.111% in 20(S)-ginsenoside Rg3-treated cells (P=0.0115). The difference between DNA methylation in the 20(R)-ginsenoside Rg3 and 20(S)-ginsenoside Rg3 groups was also statistically significant (P=0.0327).

20(R)-ginsenoside Rg3 is known to induce the global hypermethylation of DNA; therefore, the present study examined whether 20(R)-ginsenoside Rg3 affected the methylation of the promoter region of a specific gene. Zhou *et al* ([@b23-mmr-15-04-2029]) showed that ginsenoside Rg3 can inhibit HepG2 cell proliferation by downregulating the expression of VEGF. Yuan *et al* ([@b24-mmr-15-04-2029]) reported that the protein expression of anti-apoptotic Bcl2 was downregulated and the protein expression of pro-apoptotic P53 was upregulated by 20(S)-ginsenoside Rg3 in HT-29 colon cancer cells. The present study obtained similar results, which showed that P53 was upregulated, and BCL2 and VEGF were downregulated by treatment of the HepG2 cells with ginsenoside Rg3 ([Fig. 5A](#f5-mmr-15-04-2029){ref-type="fig"}). Therefore, the present study examined whether the altered gene expression levels were associated with the methylation status of the promoter. The primers used are listed in [Table I](#tI-mmr-15-04-2029){ref-type="table"}.

The results of the *Msp*I/*Hpa*II PCR analysis of DNA methylation alterations in BCL2, VEGF and P53 genes induced by ginsenoside Rg3 treatment are shown in [Fig. 5](#f5-mmr-15-04-2029){ref-type="fig"}. Alterations in DNA methylation at the CCGG sequence (2371--2374 bp) were identified in the promoter of BCL2 induced by ginsenoside Rg3, compared with the untreated control. As shown in [Fig. 5B](#f5-mmr-15-04-2029){ref-type="fig"}, no significant amplification band was detected in the 20(R)-ginsenoside Rg3-treated sample digested by *Hpa*II or *Msp*I, or in the 20(S)-ginsenoside Rg3-treated sample digested by *Msp*I. However, a weak specific band was observed in the 20(S)-ginsenoside Rg3-treated sample digested by *Hpa*II. These data indicated that the cytosine demethylation at this site was induced by ginsenoside Rg3, and that 20(R)-ginsenoside Rg3 had a higher potential to induce methylation at this site, compared with 20(S)-ginsenoside Rg3. Alterations in DNA methylation at the CCGG sequence (1,981--1,984 bp) in the VEGF promoter are shown in [Fig. 5C](#f5-mmr-15-04-2029){ref-type="fig"}. No significant differences were found in the amplification profiles among the three groups, which indicated that the DNA methylation status was not altered following ginsenoside Rg3 treatment. Alterations in DNA methylation at the CCGG sequence (5,641--5,644 bp) in the P53 promoter are shown in [Fig. 5D](#f5-mmr-15-04-2029){ref-type="fig"}, and an amplification band was found in the untreated control and 20(R)-ginsenoside Rg3-treated sample digested by *Hpa*II, however, no band was observed for the 20(S)-ginsenoside Rg3-treated sample digested by *Hpa*II. These data indicated that DNA methylation was decreased upon treatment with 20(S)-ginsenoside Rg3 at this site, whereas the DNA methylation status remained unchanged ([Table II](#tII-mmr-15-04-2029){ref-type="table"}). If the band patterns remained unchanged, compared with those of the untreated control group, it was scored 0. If the patterns showed that cytosine methylation was increased, it was scored 1. If the patterns showed that cytosine methylation was decreased, it was scored 2. The results of the *Msp*I/*Hpa*II PCR analysis showed that the percentages of CCGG sites remaining unchanged were 52 and 64% following treatment with 20(R)-ginsenoside Rg3 and 20(S)-ginsenoside Rg3, respectively. The percentages of methylated bands were 24 and 16% in the 20(R)-ginsenoside Rg3 and 20(S)-ginsenoside Rg3-treated groups, whereas the percentages of demethylated bands were 24 and 20% in the 20(R)-ginsenoside Rg3- and 20(S)-ginsenoside Rg3-treated group, respectively. From the data in [Table II](#tII-mmr-15-04-2029){ref-type="table"}, it was found that the level of DNA methylation was decreased at the promoter region of P53 and BCL2 in cells treated with 20(S)-ginsenoside Rg3, and that the gene expression of P53 was increased, whereas that of BCL2 was decreased. The level of DNA methylation was increased in the promoter region of VEGF and decreased in that of P53 upon treatment with 20(R)-ginsenoside Rg3. In addition, the gene expression of VEGF was decreased, whereas that of P53 was increased. These results indicated that gene expression was not only associated with the level of DNA methylation, but was also associated with specific sites in the promoter region of the gene.

### DNMT1 is upregulated, and DNMT3a and DNMT3b are downregulated by ginsenoside Rg3

The expression levels of DNMTs are closely linked to DNA methylation patterns. To investigate the molecular mechanism of cytosine methylation induced by ginsenoside Rg3, the mRNA levels of DNMT1, DNMT3a and DNAMT3b were measured using RT-qPCR analysis following the treatment of HepG2 cells with ginsenoside Rg3 for 24 h. As shown in [Fig. 6](#f6-mmr-15-04-2029){ref-type="fig"}, the exposure of HepG2 cells to ginsenosides Rg3 significantly increased the mRNA expression of DNMT1, compared with that in the untreated cells (P\<0.001). However, the mRNA expression levels of DNMT3a and DNMT3b showed significant decreases following exposure to ginsenoside Rg3 (P\<0.001), compared with the untreated cells, particularly the mRNA level of DNMT3a, which was reduced to \<0.25% of that in the untreated cells. Therefore, 20(S)-ginsenoside Rg3 treatment differentially regulated the expression of DNMT, possibly resulting in a decrease of global demethylation.

Discussion
==========

Several reports have demonstrated that ginsenoside Rg3 has pharmacological actions through regulating gene expression ([@b25-mmr-15-04-2029]). In the present study, the CCK8 data showed that the ability of 20(S)-ginsenoside Rg3 to inhibit HepG2 cell growth was more marked, compared with that of 20(R)-ginsenoside Rg3. The HPLC assay also demonstrated that 20(S)-ginsenoside Rg3 induced a more marked reduction in global DNA methylation, compared with 20(R)-ginsenoside Rg3. DNA hypomethylation has been reported in hepatocellular carcinoma and hypomethylation is associated with DNA damage, the promotion of carcinogenesis and activation of tumor suppressor genes ([@b16-mmr-15-04-2029]). Thus, DNA hypomethylation induced by ginsenoside Rg3, particularly 20(S)-ginsenoside Rg3, may be responsible for the inhibition of HepG2 cell proliferation.

The present study further investigated the effect of ginsenoside Rg3 on the methylation of the promoter regions of specific genes. In total, three genes were selected, which are closely associated with tumor angiogenesis, growth and apoptosis. P53 is important in apoptosis, genomic stability and the inhibition of angiogenesis, and its expression is increased by ginsenoside-Rg3 treatment ([@b26-mmr-15-04-2029]). VEGF stimulates vasculogenesis and angiogenesis. The overexpression of VEGF can cause vascular disease and the development of cancer. A decrease in its expression is induced by 20-ginsenoside Rg3 ([@b23-mmr-15-04-2029]). Bcl2 inhibits cell apoptosis and is classified as an oncogene. The expression was increased by 20-ginsenoside Rg3 ([@b5-mmr-15-04-2029]). Classically, hypermethylation of the promoter region is associated with gene silencing, and hypomethylation of the promoter region is correlated with gene activation. In the present study study, it was found that hypomethylation of the promoter region of P53 was consistent with gene activation. DNA methylation of the promoter regions of BCL2 were unchanged or decreased, however, the methylated sites of the promoter region and the gene expression were altered, suggesting that the DNA methylation level and the specific methylated site of the promoter region may be important for gene expression.

DNMTs are responsible for continued and *de novo* DNA methylation. DNMT1 maintains the DNA methylation status by maintaining the transfer of methyl groups to the newly synthesized DNA strands during DNA replication. DNMT3a and DNMT3b introduce the novel methylated cytosine site to the unmodified cytosine residues. Oh *et al* ([@b27-mmr-15-04-2029]) reported that the DNA methylation and expression of DNMT1, DNMT3a and DNMT3b were higher in hepatocellular carcinoma, compared with those in normal liver tissue. In the present study, it was found that treatment with ginsenoside Rg3 increased the relative mRNA levels of DNMT1, but significantly reduced the levels of DNMT3a and DNMT3b. Therefore, low expression levels of DNMT3a and DNMT3b may account for decreased methylation, although high levels of DNMT1 expressed during DNA replication maintained the methylation pattern.

20(S)-Ginsenoside Rg3 and 20(R)-ginsenoside Rg3 have exhibited stereo-specific effects in several studies. For example, Kim *et al* ([@b19-mmr-15-04-2029]) showed that 20(R)-ginsenoside Rg3 regulates the expression of multiple genes during the initiation of the transforming growth factor-β1-induced epithelial-mesenchymal transition and suppresses lung cancer development, whereas 20(S)-ginsenoside Rg3 does not. Park *et al* ([@b20-mmr-15-04-2029]) showed that 20(S)-ginsenoside Rg3 has more potent anticancer activity, compared with 20(R)-ginsenoside Rg3 in inducing human gastric cancer cell apoptosis. In the present study, 20(S)-ginsenoside Rg3 exhibited more potent antiproliferative effects on HepG2 cells and induced a more marked reduction in the methylation of global DNA and CpG islands, compared with 20(R)-ginsenoside Rg3, and reduced the expression levels of DNMT3a and DNMT3b. Thus, the different ginsenoside Rg3 epimers exhibit different stereo-specific effects in different types of cell, and selection of the appropriate epimer is required for treating different diseases.

In conclusion, data obtained in the present study indicated that ginsenoside Rg3 inhibited HepG2 cell proliferation in a dose-dependent manner, induced a reduction in the methylation of global genomic DNA and, for a promoter region of a specific gene, upregulated the expression of DNMT1 and downregulated the expression of DNMT3a and DNMT3b. In addition, 20(S)-ginsenoside Rg3 exhibited superior biological activity, compared with 20(S)-ginsenoside Rg3. These data indicated that 20(S)-ginsenoside Rg3 may offer increased potential, compared with 20(R)-ginsenoside Rg3, as an adjuvant treatment for hepatocellular carcinoma.
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![Chemical structure and HPLC chromatogram of 20(R)-ginsenoside Rg3 and 20(S)-ginsenoside Rg3. The X-axis shows the retention time and the Y-axis shows the voltage. The position of the asymmetric carbon atom in ginsenoside Rg3 is marked with a red circle. From the HPLC chromatograms of standards, the 20(R)-ginsenoside Rg3 retention time was \~11.5 min, compared with the 20(S)-ginsenoside Rg3 retention time of 10.5 min. (A) R type; (B) S type. HPLC, high performance liquid chromatography.](MMR-15-04-2029-g00){#f1-mmr-15-04-2029}

![Inhibitory effect of ginsenoside Rg3 on HepG2 cell proliferation. (A) Growth inhibition curve for HepG2 cells treated with ginsenoside Rg3. HepG2 cells were treated with various concentrations (0, 7.81, 15.63, 31.25, 62.5, 125, 250 and 500 µg/ml) of ginsenoside Rg3 using a doubling dilution every 48 h, and cell viability was measured using a Cell Counting Kit-8 assay. (B) Linear regression equation of logarithm (base 10) concentration and inhibition ratio. The X-axis shows the logarithm (base 10) concentration of ginsenoside Rg3, and the Y-axis shows the mean value of the inhibition ratio.](MMR-15-04-2029-g01){#f2-mmr-15-04-2029}

![Chromatogram and curve for standard dC and 5-MedC. (A) Chromatogram of standard nucleotide mixture. The same concentrations of a mixture of 5-MedC, dG, dT, dC and dA were diluted into various concentrations and detected using high performance liquid chromatography. dC and MedC are marked on the chart. The X-axis shows retention time and the Y-axis shows the voltage. (B) Linear regression curves for the dC and MedC. The X-axis shows the concentration of dC and MedC, and the Y-axis shows the peak area value. 5-MedC, 5-methyl-2′-deoxycytidine; dC, 2′-deoxycytidine.](MMR-15-04-2029-g02){#f3-mmr-15-04-2029}

![Alterations in DNA methylation in HepG2 cells treated with ginsenoside Rg3. HepG2 cells were left untreated, or were treated with 326.84 µg/ml 20(R)-ginsenoside Rg3 or 178.03 µg/ml 20(S)-ginsenoside Rg3, and the DNA was purified and hydrolyzed prior to detection using high performance liquid chromatography. The percentage of cytosine methylation was calculated, and the values in the treatment groups were compared with those in the untreated group. \*P\<0.05, vs. control.](MMR-15-04-2029-g03){#f4-mmr-15-04-2029}

![Effect of ginsenoside Rg3 on the gene expression and promoter region DNA methylation of P53, BCL2 and VEGF. (A) Effect of ginsenoside Rg3 on the mRNA expression of Bcl2, p53 and VEGF. The values in the treated groups were compared with those in the untreated control group (\*P\<0.05 and \*\*P\<0.01). (B) Example of the effect of ginsenoside Rg3 on DNA methylation at the promoter region of Bcl2. (C) Example of the effect of ginsenoside Rg3 on DNA methylation at the promoter region of VEGF. (D) Example of the effect of ginsenoside Rg3 on the DNA methylation at the promoter region of P53. BCL2, B cell lymphoma 2; VEGF, vascular endothelial growth factor; L, DNA ladder; U, undigested; M, digested with *Msp*I; H, digested with *Hpa*II.](MMR-15-04-2029-g04){#f5-mmr-15-04-2029}

![Effect of ginsenoside Rg3 on the expression of DNMT1 and DNMT3. \*P\<0.05 and \*\*P\<0.01, vs. untreated control. DNMT, DNA methyltransferase.](MMR-15-04-2029-g05){#f6-mmr-15-04-2029}

###### 

Primers.

  Primer   Primer sequence (3′-5′)     Position (bp)   Gene     NCBI accession no.
  -------- --------------------------- --------------- -------- --------------------
  XZ-82    cagagtcacctgtcttcacag       1617--1637      BCL2     EU119400
  XZ-83    tctagccgtgtatgagagtgtg      1750--1772      BCL2     EU119400
  XZ-84    acacactctcatacacggctag      1750--1751      BCL2     EU119400
  XZ-85    cgccatgaaaacaagggctg        1915--1934      BCL2     EU119400
  XZ-86    cagcccttgttttcatggcg        1915--1934      BCL2     EU119400
  XZ-87    gccttctgctcaggcctg          2060--2077      BCL2     EU119400
  XZ-88    caggcctgagcagaaggc          2060--2077      BCL2     EU119400
  XZ-89    gcccgctccgctgcgc            2154--2169      BCL2     EU119400
  XZ-90    gcgcagcggagcgggc            2154--2169      BCL2     EU119400
  XZ-91    gttaaaggcgccgcggcag         2250--2268      BCL2     EU119400
  XZ-94    gaaccgtgtgacgttacgcac       2344--2364      BCL2     EU119400
  XZ-95    caccttcgctggcagcg           2528--2544      BCL2     EU119400
  XZ-96    caggaggaggagaaagggtg        2647--2666      BCL2     EU119400
  XZ-97    ggatgactgctacgaagttctc      2724--2745      BCL2     EU119400
  XZ-98    gcttctagcgctcggcac          2828--2845      BCL2     EU119400
  XZ-99    gacggaggcaggaatcctc         2926--2944      BCL2     EU119400
  XZ-100   gaggattcctgcctccgtc         2926--2944      BCL2     EU119400
  XZ-101   gcacaggcatgaatctctatccac    3006--3028      BCL2     EU119400
  XZ-102   gtggatagagattcatgcctgtg     3006--3028      BCL2     EU119400
  XZ-103   gcggcggcagatgaattac         3109--3127      BCL2     EU119400
  XZ-104   tctcgagctcttgagatctc        3144--3163      BCL2     EU119400
  XZ-105   gattcccagacttctgcttcac      3194--3215      BCL2     EU119400
  XZ-106   gccagactccacagtgcatac       1370--1390      VEGF     AF095785
  XZ-107   ctgagaacgggaagctgtgtg       1442--1462      VEGF     AF095785
  XZ-108   ccattccctctttagccagag       1743--1763      VEGF     AF095785
  XZ-109   cattcacccagcttccctgtg       1806--1826      VEGF     AF095785
  XZ-110   cactccaggattccaacagatc      1930--1951      VEGF     AF095785
  XZ-111   gagccgttccctctttgctag       2017--2037      VEGF     AF095785
  XZ-112   acgtaacctcactttcctgctc      2053--2074      VEGF     AF095785
  XZ-113   ccaccaaggttcacagcctg        2142--2161      VEGF     AF095785
  XZ-114   caggcttcactgggcgtc          2199--2216      VEGF     AF095785
  XZ-115   agcctcagcccctccacac         2240--2258      VEGF     AF095785
  XZ-116   tgtggaggggctgaggctc         2241--2259      VEGF     AF095785
  XZ-117   gatcctccccgctaccag          2347--2364      VEGF     AF095785
  XZ-118   ctggtagcggggaggatc          2347--2364      VEGF     AF095785
  XZ-119   gaatatcaaattccagcaccgag     2483--2505      VEGF     AF095785
  XZ-120   cggtgctggaatttgatattcattg   2485--2509      VEGF     AF095785
  XZ-121   aagccgtcggcccgattc          2606--2623      VEGF     AF095785
  XZ-162   ctccatttcctttgcttcctc       4908--4928      P53      NG_017013
  XZ-163   ctggcacaaagctggacagtc       4964--4984      P53      NG_017013
  XZ-164   cttctcaaaagtctagagccac      5058--5079      P53      NG_017013
  XZ-165   gcgtgtcaccgtcgtggaaag       5141--5161      P53      NG_017013
  XZ-166   tggagctttggggaaccttgag      5422--5443      P53      NG_017013
  XZ-167   gatgtgcaaagaagtacgctttag    5449--5472      P53      NG_017013
  XZ-168   ctaaagcgtacttctttgcacatc    5449--5472      P53      NG_017013
  XZ-169   cagacctcaatgctttgtgcatc     5510--5532      P53      NG_017013
  XZ-170   tcctagtgaaaactggggctc       5592--5612      P53      NG_017013
  XZ-171   gttgtgggaccttagcagcttg      5651--5672      P53      NG_017013
  XZ-172   caagctgctaaggtcccacaac      5651--5672      P53      NG_017013
  XZ-173   atcgctccaggaaggacaaaggtc    5678--5701      P53      NG_017013
  XZ-174   gacctttgtccttcctggagcgat    5678--5701      P53      NG_017013
  XZ-175   ctggtttagcacttctcacttccac   5761--5785      P53      NG_017013
  XZ-176   gtggaagtgagaagtgctaaaccag   5761--5785      P53      NG_017013
  XZ-177   ggcagaaatgtaaatgtggagc      5853--5874      P53      NG_017013
  XZ-48    acaaagaccaggatgagaag        333--352        DNMT1    AF180682
  XZ-49    cttctcatctttctcgtctc        576--595        DNMT1    AF180682
  XZ-52    cagaagcgggcaaagaacag        659--676        DNMT3a   AF331856
  XZ53     cttgcgcttgctgatgtagtag      802--823        DNMT3a   AF331856
  XZ-56    cagagtatcaggatgggaag        965--984        DNMT3b   AF331857
  XZ-57    agtttgtctgcagagacctc        1132--1151      DNMT3b   AF331857
  XZ-60    gacctcaactacatggtttac       175--195        GAPDH    M33197
  XZ-61    tgatgggatttccattgatg        264--283        GAPDH    M33197
  XZ-62    aggtgcatgtttgtgcctgtc       875--895        P53      AB082923
  XZ-63    tcttgcggagattctcttcctc      916--937        P53      AB082923
  XZ-64    gctgggatgcctttgtggaac       2039--2059      BCL2     M13994
  XZ-65    tgagcagagtcttcagagacag      2102--2122      BCL2     M13994
  XZ-66    ccaacatcaccatgcagattatg     315--337        VEGF     AY047581
  XZ-67    Tgctgtaggaagctcatctctc      369--390        VEGF     AY047581

BCL2, B cell lymphoma 2, VEGF, vascular endothelial growth factor; DNMT, DNA methyltransferase.

###### 

*Msp*I/*Hpa*II polymerase chain reaction assay.

                  Methylation score                                                             
  --------------- ------------------- ------------------------------------------------ -------- --------
  Bcl2            XZ-82/XZ-83         1701--1704; 1715--1718                           0        0
  Bcl2            XZ-84/XZ-85         1903--1906                                       0        0
  Bcl2            XZ-86/XZ-87         1977--1980; 1982--1985; 2000--2003               1        1
  Bcl2            XZ-88/XZ-89         2141--2144                                       0        0
  Bcl2            XZ-90/XZ-91         2176--2179; 2181--2184; 2198--2199; 2225--2228   0        2
  Bcl2            XZ-94/XZ-95         2371--2374                                       2        0
  Bcl2            XZ-96/XZ-97         2673--2676; 2689--2692                           0        0
  Bcl2            XZ-98/XZ-99         2844--2947                                       0        0
  Bcl2            XZ-100/XZ-101       2946--2949                                       1        2
  Bcl2            XZ-102/XZ-103       3095--3098                                       0        0
  Bcl2            XZ-104/XZ-105       3163--3166                                       2        0
  Bcl2 total                                                                           1: 18%   1: 9%
                                                                                       2: 18%   2: 18%
  VEGF            XZ-106/XZ-107       1435--1438                                       2        1
  VEGF            XZ-110/XZ-111       1981--1984                                       0        0
  VEGF            XZ-112/XZ-113       2120--2123                                       1        0
  VEGF            XZ-114/XZ115        2225--2228                                       0        0
  VEGF            XZ-116/XZ-117       2275--2278; 2285--2288; 2299--2302               1        1
  VEGF            XZ-118/XZ-119       2384--2385                                       1        0
  VEGF            XZ-120/XZ-121       2512--2515                                       2        2
  VEGF total                                                                           1: 42%   1: 29%
                                                                                       2: 29%   2: 14%
  P53             XZ-162/XZ163        4928--4931                                       0        1
  P53             XZ-164/XZ-165       5108--5111                                       2        2
  P53             XZ-168/XZ-169       5476--5479                                       1        0
  P53             XZ-170/XZ-171       5641--5644                                       0        2
  P53             XZ-172/XZ-173       5675--5678                                       2        0
  P53             XZ-174/XZ-175       5717--5720                                       0        0
  P53             XZ-176-XZ-177       5831--5834                                       0        0
  P53 total                                                                            1: 14%   1: 14%
                                                                                       2: 29%   2: 29%
  Overall total                                                                        1: 24%   1: 16%
                                                                                       2: 24%   2: 20%

0, unchanged; 1, methylation; 2, demethylation; Bcl2, B cell lymphoma 2, VEGF, vascular endothelial growth factor.
